Abstract. Activation of HER-2/neu leads to multiple signalling cascades and plays a vital role in cell survival and growth. We used a signal transduction antibody array to characterize the tyrosine phosphorylation profiles in heregulin (HRG ·1)-treated BT474 breast cancer cells, and identified a group of 80 molecules in which tyrosine phosphorylation was highly regulated by HRG-enhanced HER-2/ neu signalling. These phosphoproteins included many known HER-2/neu-regulated molecules (e.g., SHC, Akt, Syk and Stat1) and proteins that had not been previously linked to HER-2/neu signalling, such as Fas-associated death domain protein (FADD), apoptosis repressor with CARD domain (ARC), and the tumour suppressor, protein phosphatase type 2A (PP2A). Pharmacological inhibition with HER-2 inhibitor AG825, PI3K inhibitor LY294002, MEK1/2 inhibitor PD98095, and p38MAPK inhibitor SB203580 confirmed that PP2A phosphorylation was modulated by the complicated, HER-2/neu-driven downstream signal network, with the PI3K and MEK1/2 positively, while the p38MAPK negatively regulating its tyrosine phosphorylation. In breast tumour specimens, expression of tyrosine-phosphorylated PP2A (pY307-PP2A) was highly increased in the HER-2/neu positive breast tumours, and significantly correlated to tumour progression, thus enhancing its potential prognostic value. Our data provide meaningful information in the elucidation of the HER-2-driven tyrosine phosphorylation network, and in the development of phosphopeptide-related targets as prognostication indicators.
Introduction
ErbB2, the HER-2/neu-encoded transmembrane protein, is a member of the family of receptor tyrosine kinases (RTKs) (1) . The RTKs command central roles in several signal transduction pathways regulating cell proliferation, differentiation, and survival (2) . Constitutive activation of HER-2 occurs in 20-30% of breast cancers and is associated with poorer prognosis and a more aggressive phenotype (3) . Clinically, targeting HER-2 with a monoclonal antibody, Herceptin, to inhibit its kinase activity is an effective supplementary therapy for HER-2 positive breast cancer patients. However, relapse or resistance to this chemotherapy has frequently occurred and alternative treatment regimes have to be developed (4) . A full understanding of the contribution of HER-2 signalling to oncogenesis is a critical step in the search for novel and more effective therapeutic targets for breast cancer.
HER-2/neu is a ligandless receptor with an extracellular domain, a transmembrane domain and a C-terminal intracellular domain. Receptor dimerization of HER-2 with other RTK members induces the activation of its downstream signalling by autophosphorylation of tyrosine residues at its C-terminal sites and recruitment of other docking molecules, such as Grb2, Stat and Shc. The key HER-2-regulated signalling pathways include the Ras/Raf/mitogen-activated protein kinase (MAPK) and phosatidylinositol-3 kinase (PI3K) pathways, which are essential for cell proliferation and transformation (5) . However, the detailed signalling network regulated by HER-2 signalling is largely unclear. Dissecting the complexity of protein phosphorylation and dephosphorylation events in tumour cells remains an area of intense research.
Recently, a group of tyrosine-phosphorylated proteins regulated by HER-2 signalling have been identified using proteomics strategies (6) (7) (8) (9) (10) . By profiling the tyrosinephosphorylated proteins in ErbB2-overexpressing breast and ovarian cancer cell lines, Mukherji et al found that the adaptor/docking proteins, kinases and other proteins involved in cell proliferation and migration were highly tyrosinephosphorylated and treatment with Herceptin attenuated their phosphorylation (6) . In addition, several uncharacterized RNA binding proteins, e.g., SRRM2 and SFRS9, were also highly phosphorylated in the HER-2-overexpressed cells (6) . When these cells were treated with Heregulin ·1 (HRG), an EGF-like growth factor, proteins such as paxillin, FAK and GIT1 were highly tyrosine-phosphorylated and the signal network involved in cell migration was amplified (9) . Bose et al reported that inhibition of HER-2 signalling with the specific tyrosine kinase inhibitor, PD168393, led to the identification of several previously uncharacterized phosphoproteins, including Axl tyrosine kinase, the adaptor protein Fyb and the calcium-binding protein PDCD-6/Alg-2 (7). It is possible, with appropriate use of different complementary phosphoproteomics investigative methods, to dissect, identify and characterize the tyrosine-phosphorylated proteins in the HER-2-driven signal network and achieve a better understanding of the mechanisms underlying the cellular response. Profiling the tyrosine-phosphorylated proteome is the logical first step to elucidate the dynamic phosphorylation and dephosphorylation of a variety of proteins which constitute the complicated network controlling cellular behaviour under the influence of receptor tyrosine kinase signaling.
To further understand the complexity of tyrosinephosphorylation profiles of the interactive downstream proteins of the HER-2 signalling, we treated the ErbB2-expressing BT474 cells with HRG and investigated the differential tyrosine phosphorylation of various signal modulators using an antibody array. We identified a group of signal modulators which are differentially tyrosinephosphorylated by HRG-enhanced HER-2 signalling. Postmodification of these signal modulators are diversely involved in multiple cellular functions, primarily in cell apoptosis, signal transduction, transcription, cell cycle regulation, and cell proliferation. In particular, we investigated the role of HER-2 signalling in modulating tyrosine phosphorylation of protein phosphatase 2A (PP2A), one of the identified signal modulators. Inhibition studies with various inhibitors showed that the PI3K/Akt and Raf/Ras/MEK pathways positively regulate, whereas the p38MAPK pathway negatively regulates the tyrosine phosphorylation of PP2A. Furthermore, as the level of tyrosine-phosphorylated PP2A at tyrosine 307 (pY307-PP2A) was found to be increased in the HER-2-positive breast cancer subgroup, the clinical significance of this as a prognostication biomarker of cancer progression was further assessed in a panel of 206 clinical specimens.
Materials and methods
Materials. LY294002, a specific inhibitor of the p110 catalytic subunit of PI3K, AG825, a specific inhibitor of HER-2/neu tyrosine kinase, and SB203580, a specific inhibitor of p38MAPK, were purchased from Calbiochem (San Diego, CA, USA). PD98059, a specific inhibitor of MEK, was from US Biological (Swampscott, MA, USA). Heregulin ·1 (HRG), a ligand of ErbB3 and HER-2/neu (ErbB2), was from Neomarkers (Fremont, CA). All the inhibitors were dissolved in dimethyl sulfoxide (DMSO) and stored at -20˚C in the dark as stock solutions until use.
The following antibodies were used for immunoblot analysis: rabbit anti-phospho-HER-2/neu (Tyr1248) (1:1000), rabbit anti-ERK1/2 (1:1000), mouse anti-phospho-ERK1/2 (Tyr204) (1:500), rabbit anti-ARC (1:200), rabbit anti-FADD (1:200), rabbit anti-N-Shc (1:1000), rabbit antiphospho-Shc (Tyr239/240) (1:200), rabbit anti-PP2A (1:200), rabbit anti-phospho-PP2A (Tyr307) (1:1000), mouse anti-Stat1 (1:200), and rabbit anti-phospho-Stat1 (Tyr701) (1:200), were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-phosphotyrosine 4G10 (1:1000) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY), mouse anti-HER-2/neu (1:1000) from Neomarkers, mouse anti-Ezrin (1:100) from BD Biosciences PharMingen (San Diego, CA, USA) and horseradish peroxidase (HRP)-conjugated phosphotyrosine (1:1000) from Hypromatrix (Worcester, MA, USA). Rabbit anti-AKT (1:1000) and rabbit anti-phospho-AKT (Ser473) (1:1000) were obtained from Cell Signalling Technology (Beverley, MD, USA).
Cell culture and treatment. The human HER-2/neu positive BT474 breast cancer cell line was grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37˚C in a humidified 5% CO 2 incubator. For HRG stimulation, BT474 cells (70-80% confluence) were serum-starved for 20 h and HRG (final concentration 3 nM) was added into the medium. Cells were then incubated for the indicated time periods (5, 10 and 30 min). For the inhibitor treatment (with AG825, SB203580, PD98059 and LY294002), the BT474 cells (at 70-80% confluence) were fed with fresh medium, supplemented with different individual inhibitors at the indicated concentrations (as stated in the context) for 10 and 30 min. Cells were then harvested for Western blotting. Cells treated with an equal volume of DMSO were used as control. Each treatment was performed in triplicates and each treatment was repeated thrice.
To prepare cell lysates, BT474 cells were collected after trypsin-treatment and washed 3 times with ice-cold phosphate-buffered saline (PBS, pH 7.4). Cells were resuspended in cold RIPA buffer (1% Igepal, 1% sodium deoxycholate, 0.15 M sodium chloride, 0.01 M sodium phosphate, pH 7.2, and 2 mM EDTA) supplemented with protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA) and phosphatase cocktail inhibitors I and II (1:100; Sigma-Aldrich, Steinheim, Germany), and kept on ice for 30 min. Cell lysates were then centrifuged at 4˚C and the supernatants were collected. Protein concentrations were determined using the Coomassie Plus Bradford assay (Pierce, Rockford, IL, USA).
Identification of tyrosine-phosphorylated proteins using signal transduction antibody array. The serum-starved BT474 cells were treated with HRG (3 nM) or with DMSO for 30 min and the total proteins were extracted. After the array was blocked with 5% non-fat milk in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 h, equal amounts of proteins from both the HRG-treated and the DMSO-treated (control) cells were diluted to 1 mg/ml and then probed with the Signal Transduction Antibody Array (Hypromatrix), respectively, for 2 h at room temperature, according to the manufacturer's instructions. The arrays were washed with TBST buffer and further incubated with HRP-conjugated anti-phosphotyrosine antibody (Hypromatrix) for 2 h with gentle agitation. The chemiluminescent signals were then visualized using the SuperSignal ® West Pico Chemiluminescent Substrate (Pierce) and captured with the MULTI GENIUS Bio Imaging System (Syngene, Frederick, MD, USA). The signal intensity of each spot was analyzed using the GeneTools software (Syngene). The relative tyrosine phosphorylation level of each protein was interpreted as the ratio of the spot intensity in the HRG-treated sample to the spot intensity in the control sample.
Immunoprecipitation and Western blotting. For immunoprecipitation, 500 μg of proteins was immunoprecipitated with selective antibodies (anti-FADD, anti-ARC, and antiEzrin) at 4˚C and gently agitated overnight. Protein ASepharose or protein G-Sepharose (GE Healthcare, Uppsala, Sweden) was then added and the mixture incubated at 4˚C for 2 h. The agarose beads were collected, washed and resuspended in 50 μl of sample buffer containing 50 mM Tris-HCl, pH 7.6, 2% SDS, 10% glycerol, 10 mM DTT and 0.2% bromophenol blue. After boiling for 5 min, samples were cooled down on ice and analyzed by Western blotting. Tyrosine phosphorylation was detected using anti-phosphotyrosine antibody. Briefly, proteins were separated by SDS-PAGE and then transferred to Hybond-P PVDF membrane (GE Healthcare). The filters were blocked in 5% non-fat milk in TBST for 1 h at room temperature and probed with the respective antibodies at 4˚C overnight. HRP-conjugated goat anti-mouse IgG (1:5000, Upstate) or HRP-conjugated goat anti-rabbit IgG (1:10000, ZyMED Laboratories Inc., San Francisco, CA) was applied after the filters were washed with TBST. The chemiluminescent signals were then detected and captured, as stated in the previous section.
Two-dimensional electrophoresis and immunoblotting.
Protein separation by 2-dimensional electrophoresis (2-DE) was carried out as previously described (11) . Briefly, 50 μg of protein was mixed with 125 μl of rehydration buffer (7 M urea, 2% CHAPS, 3.5 mg DTT and 1% IPG buffer, pH 3.0-10.0 or pH 4.0-7.0) and separated using precast Immobiline IPG DryStrip (70 mm, pH 3.0-10.0 or pH 4.0-7.0, GE Healthcare) with the Ettan™ IPGphor™ Isoelectric Focusing System (GE Healthcare). Prior to SDS-PAGE, the strips were then equilibrated for 20 min in equilibration buffer (50 mM Tris-HCl, pH 8.8, 30% glycerol, 7 M urea, 2% SDS) containing DTT (100 mg per strip), followed by further equilibration with the same buffer with iodoacetamide (250 mg per strip). Protein transfer and immunoblotting were performed and signals were detected, as described above.
Immunohistochemistry and tissue microarray. A breast disease spectrum tissue array including 206 cases was purchased from US Biomax (Rockville, MD, USA). The array contained 32 metastatic carcinomas, 68 invasive ductal carcinomas, 22 each of lobular and intraductal carcinomas, 16 normal tissues, and 44 other non-malignant tissues. Immunohistochemical (IHC) staining of pY307-PP2A was conducted using the Dako Envision system (11) . Briefly, sections were deparaffinized, rehydrated, and the antigens unmasked using the Dako ® Target Retrieval Solution. Endogenous peroxidases were removed using 3% hydrogen peroxide, followed by incubating with anti-pY307-PP2A (1:25) antibody for 1 h at room temperature. The sections were further treated with labelled dextran polymer conjugated with HRP for 30 min and incubated with DAB + -substrate chromogen solution for 5-10 min. Sections were counterstained with Mayer's hematoxylin and mounted. The degree of staining of pY307-PP2A was scored as 0 (negative to weak), 1 (moderate) and 2 (strong), according to the staining intensity of the tumour cells. Scoring was performed by two pathologists and the principal investigator, independently. Cases with discrepant scores were re-scored by the same or additional scorers, to obtain a consensus score, failing which the scores were excluded from the data analysis.
Statistical analysis. The Student's t-test was used to compare the significance of differences of relative tyrosine phosphorylation of PP2A (pY307-PP2A/PP2A) between controls and treated samples. The difference of tyrosinephosphorylated PP2A (pY307-PP2A) between different types of tissues (lymph node metastasis, malignant, nonmalignant and normal tissues) was analyzed with Fisher's exact test. Two-sided p<0.05 was considered as significant.
Results

Identification of tyrosine-phosphorylated molecules regulated
by heregulin-enhanced HER-2 signalling. HRG ·1, a ligand of ErbB3, stimulates the heterodimerization of ErbB3 with ErbB2 and activates the downstream signalling (12) . Treatment of the HER-2-expressing BT474 breast cancer cells with HRG showed the time-dependent phosphorylation of HER-2 and its key downstream modulators including AKT and ERK1/2 ( Fig. 1) . When the cells were treated for 30 min, phosphorylation of ErbB2, ERK1/2 and AKT were highly enhanced, as determined by Western blotting with the respective phospho-specific antibodies. To investigate the tyrosine-phosphorylated molecules regulated by HER-2/neu signalling, the BT474 cells were treated with HRG or DMSO (as control) for 30 min and signal transduction antibody arrays were used to study the changes of tyrosine phosphorylation of different signalling modulators. Fig. 2A shows the differential tyrosine phosphorylation patterns on the filter between the HRG-treated and control BT474 cells. We found that 80 of the 400 arrayed molecules (20%) showed significant differences in the spot intensities of treated samples vs.
controls. The tyrosine-phosphorylated and dephosphorylated proteins identified are listed in Table I .
Functional analysis (Gene Ontology) showed that these proteins are mainly involved in cell apoptosis (25%), signal transduction (25%) and transcriptional activity (16%) (Fig. 2B) . Not surprisingly, we found several known HER-2/neuregulated proteins, e.g. Src homology 2 domain-containing transforming protein (SHC), Stat-1 transcription factor, Srcrelated protein tyrosine kinases (Syk), ErbB2, and AKT, are highly tyrosine-phosphorylated after HRG treatment, which further confirms the efficiency of the antibody array in dissecting the tyrosine-phosphorylated protein profiles. Most importantly, we also found a group of proteins whose tyrosine phosphorylations have not been previously linked to HER-2 signalling. For example, cell apoptosis-related proteins such as apoptosis repressor with CARD domain protein (ARC) and FAS-associated Death Domain protein (FADD), the cell motility-associated protein villin 2 (Ezrin), and protein An anti-phosphotyrosine antibody conjugated to horseradish peroxidase (HRP) was used to detect phosphorylated tyrosines on proteins. Signals were captured with the MULTI GENIUS Bio Imaging System (Syngene) and the signal intensity of each spot was analyzed using the Syngene GeneTools software. Relative tyrosine phosphorylation level of each protein was interpreted as the ratio of spot intensity in the HRG-treated sample to the spot intensity in the control sample. Spots K4 and C7 represent p-EGFR and CD3 epsilon with reduced phosphotyrosine signals in the HRG-treated BT474 cells. Other spots (L7: HER2; S7: Ezrin; T7: FADD and H15: PP2A) show the increased phosphotyrosine signals in the HRG-treated BT474 cells. Underlined spots represent the proteins involved in cell apoptosis. (B) Grouping of identified tyrosine phosphorylated and -dephosphorylated molecules. Only the proteins with a ratio of at least 1.5-fold difference or only detected in either of the two filters were selected and functionally grouped in the pie chart.
phosphatase type 2A (PP2A), were highly tyrosine-phosphorylated in the HRG-treated BT474 cells. Interestingly, only 2 proteins, p-EGFR and CD3 epsilon ( Fig. 2A , located at K4 and C7) were found to be highly dephosphorylated under the HRG-enhanced HER-2 signalling. Collectively, we identified a large number of HER-2-regulated tyrosinephosphorylated and -dephosphorylated signal proteins, including several novel signal modulators.
To confirm the HRG-enhanced tyrosine phosphorylation of the signal proteins identified by the antibody array, we treated the BT474 cells with HRG for 30 min and analysed the tyrosine phosphorylated levels of 2 proteins (Shc and Stat1) that are directly regulated by HER-2 signalling, and 4 other proteins (FADD, ARC, Ezrin and PP2A) that had not been previously reported to be associated with HER-2 signalling, by immunoprecitation and Western blotting. As shown in Fig. 3A , HRG significantly enhanced phosphorylation of Shc and Stat1, two important mediators in the HER-2 signalling pathway (13), relative to that observed in the control cells treated with DMSO. Similarly, tyrosine phosphorylation of PP2A, Ezrin, ARC and FADD were highly increased after HRG treatment (Fig. 3B ). Immunoblot analysis of these 4 proteins after 2-DE separation revealed additional multi-spots with increased intensities, appearing on the acidic side of the main spots of PP2A, Ezrin, FADD and ARC in the HRG-treated cells (Fig. 3C) , giving further evidences of phosphorylation modification of these proteins under HRG stimulation.
HER2 signalling regulates tyrosine phosphorylation of PP2A.
PP2A is one of the major serine/threonine phosphatases involved in multi-cellular processes including regulation of different signal transduction pathways (e.g., Raf/MEK/ERK and PI3K/Akt) and control of cell cycle progression, gene transcription and protein translation (14) (15) (16) (17) . It was reported that PP2A could be inactivated by tyrosine phosphorylation in response to cell growth stimulation by EGFR or c-Src (18) . In our study, we found that PP2A was highly tyrosinephosphorylated at tyrosine 307 (pY307) in a time-dependent manner when HER-2 signalling was enhanced in the HRGtreated BT474 breast cancer cells (Fig. 4A) . To further verify the role of HER-2 signalling in the regulation of PP2A phosphorylation, we blocked the HER-2 signalling by treating BT474 cells with tyrphostin AG825, a specific HER-2 kinase inhibitor (19) . Just as the phosphorylation of HER-2 was reduced in cells treated with AG825 (100 μM), pY307 of PP2A was decreased in the same way (Fig. 4B ). These results demonstrate the regulatory role of HER-2 signalling in tyrosine phosphorylation of PP2A.
PI3K/AKT and MEK/ERK positively regulate, whereas p38
MAPK negatively regulates tyrosine phosphorylation of PP2A. HER-2 signalling activates several downstream signalling pathways, e.g., PI3K/Akt, thus leading to dysregulated cell proliferation and enhanced cell survival. To further understand the regulatory mechanism of PP2A phosphorylation driven by HER-2 signalling, different inhibitors targeting PI3K, MEK, and P38MAPK, were used to block the respective pathway and the level of phosphorylated PP2A at its tyrosine 307 residue (pY307-PP2A) was analyzed by Western blotting. As shown in Fig. 5A , when the intrinsic PI3K activity in BT474 cells was blocked with LY294002, a specific inhibitor of the p110 catalytic subunit of PI3K, the amount of pY307-PP2A formed was reduced. Similarly, a significant reduction of pY307-PP2A levels also occurred when the intrinsic MEK/ERK pathway was interrupted with the MEK I specific inhibitor, PD98059, which targets the MEK/ERK pathway (Fig. 5B) . However, the cells treated with SB203580, a specific inhibitor of p38MAPK, showed an increased level of pY307-PP2A (Fig. 5C ), implying that activation of p38MAPK reduces tyrosine phosphorylation of PP2A. This is consistent with the function of p38 as a tumour suppressor: activation of p38·/ß causes cell growth arrest, senescence and/or apoptosis while inhibition of p38·/ß interrupts their growth arrest and resume proliferation (20, 21) . The enhanced level of pY307-PP2A at the inhibitory state of p38MAPK could be attributed to inactivation of PP2A activity as a tumour suppressor, thereby facilitating cell survival. Taken together, our results clearly demonstrate that the tyrosine phosphorylation of PP2A in cells was regulated by a complex multi-signalling network, with PI3K/Akt and MEK/ERK exerting a positive effect, whereas p38MAPK has a negative effect on this essential process. Activation of PI3K or MEK could inactivate PP2A activity by enhancing its tyrosine phosphorylation. In contrast, activation of p38MAPK could activate PP2A by inhibiting its tyrosine phosphorylation.
Tyrosine-phosphorylated PP2A was highly expressed in HER-2 positive breast tumours. We next investigated the expression of PP2A and pY307-PP2A in a panel of clinical specimens. As indicated in Fig. 6A , PP2A is expressed in both the tumour and non-tumour tissues. However, PP2A (normalized to ß-actin) was highly expressed in the nontumour tissues and downregulated in the tumour tissues (Fig. 6B) , further supporting the role of PP2A as a tumour suppressor in breast cancer progression. We also found that pY307-PP2A is only detected in the tumour tissues (Fig. 6A , right panel) and the level of pY307-PP2A (normalized to ß-actin) is significantly increased in the HER-2 positive tumours, compared to the corresponding levels observed in the HER-2 negative tumours (Fig. 6D) . However, the relative phosphorylation level of PP2A (pY307-PP2A/PP2A) was not markedly enhanced in the HER-2 positive tumours (Fig. 6C) . Taking into account that phosphorylation of PP2A is a transient process under growth factor stimulation, as reported by Chen et al (18) , and as demonstrated in our present study in an in vitro cell system, this transient phenomenon may not be readily observed in the tumour specimens.
To examine whether the level of pY307-PP2A is associated with the HER-2 status in breast cancer, we performed an immunohistochemical analysis with anti-pY307-PP2A antibody on tissue sections of a tissue microarray containing 35 cases of HER-2 positive tumours and 50 cases of HER-2 negative tumours, which we had constructed using a Beecher microarrayer (22) . The extent/intensity of staining of pY307-PP2A in both types of tumours was evaluated under light microscopy and scored as negative, moderate and strong staining. We showed that pY307-PP2A was positively stained (moderate/strong) in 15 of 25 HER-2 positive tumours and 14 of 44 HER-2 negative tumours (p=0.04, Fisher's exact test, data not shown). This result further demonstrated that inactivation of PP2A by tyrosine phosphorylation strongly correlated with the HER-2 status of the breast tumours. Level of pY307-PP2A correlated with breast cancer progression. To investigate whether pY307-PP2A expression is associated with breast cancer progression, we further analyzed the level of pY307-PP2A by immunohistochemistry on the tissue microarray we purchased from Biomax, which included 206 different cases. This array contained 32 cases of metastatic carcinomas, 116 malignant carcinomas, 44 nonmalignant tissues and 16 non-tumours. Scoring of the staining intensity of each case was made by two independent pathologists and one principal investigator. The staining intensity was classified as negative and weak (score 0), moderate (score 1) and strong (score 2) to indicate the expression of pY307-PP2A in different tissue specimens. In cases in which a discrepancy was noted, a subsequent review carried out to reach a consensus was mostly but not always successful; discordant results were excluded from statistical data analysis. Representative cases with different scores are shown in Fig. 7A , B and C). Of the 34 non-malignant tissues including benign growths, hyperplasia and inflammation, only 2 cases showed strong staining intensity and 12 moderate staining intensity, whereas in the 106 malignant carcinomas, 21 cases were strongly stained and 57 moderately stained (p<0.01). Noticeably, pY307-PP2A was highly stained in 8 of the 30 metastatic carcinomas, and with a higher frequency than that observed in the malignant carcinomas, although not at a significant level (p=0.15). None of the 14 normal tissues showed high expression of pY307-PP2A. Collectively, expression of pY307-PP2A was found to be progressively increased with the disease progression of the patients being assessed (Fig. 7D ).
Discussion
Tyrosine phosphorylation is one of the central regulatory mechanisms of signal transduction in cancer progression. Proteins transiently or stably phosphorylated at tyrosine residues constitute the tyrosine phosphoproteome, a complex network leading to malignant transformation and disease. In breast cancer, HER-2 oncogene modulates cell survival and apoptosis by regulating its downstream signalling cascade of interlinked pathways, including those involving PI3K/Akt, Raf/MEK1/ERK and p38MAPK. To fully inventorize the tyrosine phosphoproteins involved in the HER-2 signalling network, phosphoproteomic profiles have been compiled using a variety of methods based on the SILAC, IMAC/ Nano-LC-MS/MS and antibody microarray platforms and novel tyrosine phosphoproteins have been identified (6, 7, 23) . These investigations were designed to support the concept that dissecting the changes in tyrosine phosphorylation of signal molecules would represent a fundamental task to elucidate the biologic/biochemical basis of disease progression and to develop therapeutic drugs targeting specific tyrosinephosphoproteins. Findings from some of these studies have provided the proof-of-concept sought. Table 1 . Identified tyrosine-phosphorylated proteins from HRG-treated BT474 cells. Functional groups Proteins  Location  Tyrosine  Functional groups  Proteins  Location  Tyrosine  on arrays phosphorylation  on arrays  phosphorylation  level 
Relative tyrosine phosphorylation is expressed as the ratio of spot intensity on filter probed with the HRG-treated samples to that on the filter treated with control sample. Only the proteins with a ratio of >1.5-fold increased (or decreased) or only detected on the filter probed with HRG-treated samples (or on the filter probed with control sample) were considered as increased (or decreased) in their tyrosine phosphorylation.
In this study, we investigated the HER-2-driven tyrosine phosphorylation profiles of the key signal modulators involved in various cellular functions using the signaling transduction antibody array (Hypromatrix), and identified 78 tyrosinephosphorylated proteins and 2 tyrosine-dephosphorylated proteins, tyrosine phosphorylation of which were stimulated or suppressed following HRG-enhanced HER-2 signalling. These differentially phosphorylated molecules are involved in diverse essential cell functions (apoptosis, transcription, cell adhesion, etc., as listed in Table I ). In addition to specific downstream proteins (e.g., Shc, Stat1 and Akt) that were previously known to be upregulated by HER-2 signalling, we also found that most of the apoptosis-related proteins, e.g., FADD and ARC, were tyrosine phosphorylated when the BT474 cells were treated with HRG (Fig. 3) , a first-time finding. Recently, Matsuyoshi et al found that FADD phosphorylation at Ser194 was regulated by the c-jun Nterminal kinase (JNK), affected cell cycle arrest and inhibited cell invasion (24) , but whether tyrosine phosphorylation of FADD inactivated its apoptotic activity remains unclear. ARC is reported to be highly expressed primarily in brain and myogenic tissues (25) . When cells are triggered by stimuli such as hydrogen peroxide, hypoxia and the Fas ligand, ARC appears to assume a protective role, inhibiting the cells from undergoing apoptosis (26, 27) . However, little is known about the mechanism by which HER-2 signalling regulates tyrosine phophorylation of ARC in cancer cells. Mapping the tyrosine phosphorylation sites and elucidating its role in cancer cells would be critical to understanding the cross-talk between HER-2 signalling and cellular apoptotic signals. In addition, Ezrin, an important member of the ezrinradixin-moesin family involved in cell surface structures and cell survival (28, 29) , was highly phosphorylated in the HRG-treated BT474 cells. Our finding was further supported by immunohistochemical study that phosphorylated ezrin was mostly found in HER-2/neu positive breast tumours (30) .
Most intriguingly, we demonstrated that PP2A, a major protein serine/threonine phosphatase that participates in many signalling pathways in mammalian cells, was highly phosphorylated at tyrosine 307 in the HRG-treated BT474 cells (Fig. 4) . PP2A modulates cell survival and apoptosis, and tyrosine phosphorylation of PP2A results in inactivation of its phosphatase activity and loss of function as a tumour suppressor. Despite full recognition of the importance of tyrosine phosphorylation in regulating its activity, the molecular mechanism of HER-2-triggered tyrosine phosphorylation of PP2A remains unknown. PP2A is a heterotrimer consisting of a 36-kDa catalytic subunit (PP2A/C), a 65-kDa structural A subunit (PP2A/A), and a variable regulatory subunit ranging in size from 50 to 130 kDa (PP2A/B) (15) . It has been found that phosphorylation at tyrosine 307 and/or methylation of the C subunit are the crucial steps in regulating PP2A activity (18, 31) . Thus the posttranslational modification of PP2A is a critical regulatory step in exerting its role in mammalian cells, especially in cancer cells where it regulates cell survival and apoptosis by manipulating the activities of the key signal molecules, such as Akt, Bax, and Calpains (17, (32) (33) (34) . Given the importance of PP2A as a multifunctional modulator, molecular regulation of PP2A activity by the intrinsic and/or extrinsic signal network decides the cell's destination. Previous studies demonstrated that the Simian virus 40 small T antigen (SV40 ST), directly inhibits the activity of PP2A in promoting cell transformation (35) . On the other hand, oncogenic signals enhanced by nonreceptor-and receptor-linked tyrosine kinases including the EGFR and the insulin receptor stimulate tyrosine phosphorylation of PP2A and thereby inhibit its activity (19) . Considering the fact that EGFR and the related HER-2 are the most prevalent oncogenes in breast cancer, we propose that HER-2 signalling may also play a key role in 'tuning' PP2A activity by tyrosine phosphorylation as well. As expected, we found that tyrosine phosphorylation of PP2A was significantly affected either by switching on HER-2 signalling with HRG or by switching off HER-2 signalling with its specific inhibitor AG825 (Fig. 4) . Our data further emphasize the importance of oncogenic signalling in regulating PP2A activity. Furthermore, the inhibitor experiments targeting PI3K, MEK1 and p38MAPK demonstrated their respective contribution to the tyrosine phosphorylation of PP2A. We found that tyrosine phosphorylation of PP2A was highly inhibited in BT474 cells by PI3K or MEK1 inhibitors, but was markedly increased in these same cells upon addition of the p38 MAPK inhibitor (Fig. 5) . These results indicate that the PI3K/Akt and Raf/MEK1/Erk pathways positively regulate, whereas the p38MAPK pathway negatively regulates PP2A activity in cancer cells. These observations are consistent with the cell survival role of activated PI3K/Akt and Raf/MEK1/Erk and with the cell pro-apoptotic role of activated p38MAPK. Our data address and add credence to the concept that the key HER-2-linked downstream pathways constitute an interactive network to regulate the phosphorylation status of PP2A. This tyrosine phosphorylation-based modification of PP2A activity by the cross-signalling pathways in cancer cells further highlights its central role in regulating cell survival and apoptotic behaviour.
PP2A had been reported to be a tumour suppressor in breast, colon and lung tumours and myeloma (36) . Seemingly in contradiction to the above study, PP2A was found to have a stimulatory effect in positively regulating Raf-1, a protooncogene upregulating the MAP kinase pathway (16) , and in the Wnt-mediated signal transduction pathway (37) . Furthermore, PP2A activity was shown to be required for cells to progress through the early phase of cell cycle to enter S phase (38) , and to exert an anti-apoptotic effect on malignant testicular germ cell tumour (39) . The contrasting functions of PP2A may be attributed to its existence as a multitasking, enzyme complex rather than as a single enzyme entity (14) . Whilst it had been reported that PP2A activity was higher in ER-positive breast cancer cell lines than in the ER-negative cell lines (40) , there is scanty information of pY307-PP2A expression in human breast tissues. To further investigate the distribution and expression of PP2A and pY307-PP2A in breast cancer specimens, and to understand whether the level of pY307-PP2A is associated with cancer progression, we tested the levels of both PP2A and pY307-PP2A in a panel of resected breast tumours. A comparison of the PP2A expression between tumour and non-tumour samples (Fig. 6B) further supported the role of PP2A as a tumour suppressor in breast cancer. Noticeably, the observation that pY307-PP2A was only detected in all the tumour samples, but not in any of the non-tumour samples (Fig. 6A and D) , strongly suggests the inactivation of PP2A in tumours. Interestingly, the relative tyrosine phosphorylation of PP2A (pY307-PP2A/PP2A) was not significantly different in the HER-2-positive and -negative tumours (Fig. 6C ). This is not surprising when one considers that as tyrosine phosphorylation induced by the oncogenic HER-2 signalling is a transient response, as verified by our data and supported by data from other studies using an in vitro cell system (18) . This transient signal may not be readily observed in tumour samples. The increased expression of pY307-PP2A in the HER-2 positive tumours is consistent with the subsequent tyrosine phosphorylation and inactivation of PP2A expressed in this subtype of tumours. Moreover, tumours with higher positive staining of pY307-PP2A were associated with patients in the later stages of breast cancer progression, most notably in those with malignancy and lymph node metastasis (Fig. 7) . This tissue microarray study supported the strong association of pY307-PP2A with tumour progression, and further highlighted the potential of pY307-PP2A as a viable target therapy to block off tumorigenesis by its inherent property of reactivating PP2A activity. The results of our study also indicate that pY307-PP2A has a potential prognostic value in determining breast cancer progression.
In summary, our tyrosine phosphoproteomics study with the antibody array identified novel signal modulators that are highly phosphorylated and/or dephosphorylated under HER-2 signalling. These molecules constitute a group of potential targets in developing novel treatment regimes to arrest tumour progression in breast cancer cells by modulating their tyrosine phosphorylation status. The complicated regulatory mechanism of PP2A phosphorylation by the downstream pathways of HER-2 signalling reveals its essential role, at least in part, in deciding the destiny of these cells: the activated PI3K-and Raf/MEK pathways stimulate PP2A phosphorylation and attenuate its activity to facilitate cell survival, whereas the activated p38 MAPK pathway reduces PP2A phosphorylation and increases its activity to accelerate cell apoptotic activity. In the clinical tumour specimens, pY307-PP2A is highly increased in the more aggressive HER-2-positive breast tumours and markedly associated with tumour progression. Our investigation further indicates pY307-PP2A is an important prognostic factor in breast cancer development.
